Health News

The Los Angeles Times and New York Times recently examined issues related to the experimental female libido drug flibanserin. On June 18, an FDA advisory panel voted 11-0 against recommending the drug for treatment of female hypoactive sexual-desire disorder. Summaries appear below…

Read more

Filed under: Women's Health
Tags: Drug, Women's Health

Related posts

• Xanodyne’s New Drug Application For The Treatment Of Heavy Menstrual Bleeding (Menorrhagia) Accepted For Filing With A Priority Review Classification (0)
  Xanodyne Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review status for its investigational proprietary formulation of tranexamic acid for the treatment of women with menorrhagia, heavy menstrual bleeding (HMB), and its accompanying symptoms. Read more [tags] Women's Health [/tags]
  
  
• Xanodyne Announces FDA Approval Of Lysteda(TM) (Tranexamic Acid) For Treatment Of Women With Heavy Menstrual Bleeding (0)
  Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia. Read more [tags] Women's [...]
  
  
• Women, Diabetics, Dementia Patients Most Likely To Fall In ‘Doughnut Hole’; Reform Seeks To Close Coverage Gap (0)
  Bloomberg BusinessWeek: "Among elderly Americans, women and those with diabetes and dementia are most likely to find themselves in the Medicare Part D drug plan 'doughnut hole,' the coverage gap that occurs after a beneficiary has reached the annual coverage limit but hasn't spent enough on drugs to qualify for catastrophic coverage... Read more [tags] Women's Health [...]
  
  
• Women’s Health Policy Report Highlights Studies From Recent Breast Cancer Conference (0)
  The following summarizes findings reported last week at the San Antonio Breast Cancer Symposium. ~ Anthracyclines: New research suggests that anthracyclines -- a class of chemotherapy drugs commonly used to treat breast cancer -- could cause more harm than benefits for breast cancer patients because they can be damaging to the heart, the Wall Street [...]
  
  
• Women Need Clot-Busting Therapy After Stroke (0)
  New research shows women who don't receive a clot-busting drug after a stroke fare worse than men who are not treated. The study is published in the March 2, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology. "Women need to be treated for stroke as soon as [...]